CN110105449B

CN110105449B - Antibody specifically binding VEGF and application

Info

Publication number: CN110105449B
Application number: CN201910267542.8A
Authority: CN
Inventors: 吕鹏辉
Original assignee: Zhejiang Joyevs Biotechnology Co ltd
Current assignee: Zhejiang Joyevs Biotechnology Co ltd
Priority date: 2019-04-03
Filing date: 2019-04-03
Publication date: 2021-01-12
Anticipated expiration: 2039-04-03
Also published as: CN110105449A

Abstract

The invention provides a monoclonal antibody specifically binding VEGF and application thereof, wherein the antibody comprises: CDR-L1 comprising the amino acid sequence of SEQ ID NO:01, and/or CDR-L2 comprising the amino acid sequence of SEQ ID NO:02, and/or CDR-L3 comprising the amino acid sequence of SEQ ID NO:03, and/or CDR-H1 comprising the amino acid sequence of SEQ ID NO:04, and/or CDR-H2 comprising the amino acid sequence of SEQ ID NO:05, and/or CDR-H3 comprising the amino acid sequence of SEQ ID NO: 06.

Description

Antibody specifically binding VEGF and application

Technical Field

The invention relates to the field of monoclonal antibodies, in particular to an antibody specifically binding VEGF and application thereof.

Background

Vascular Endothelial Growth Factor (VEGF), also known as Vascular Permeability Factor (VPF), is a highly specific Vascular endothelial cell growth factor that has the effects of promoting increased Vascular permeability, extracellular matrix degeneration, Vascular endothelial cell migration, proliferation, and angiogenesis.

The vascular endothelial growth factor family has many subtypes, including VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E and Placental Growth Factor (PGF), and VEGF is commonly referred to as VEGF-A. VEGF-A promotes neovascularization and increases vascular permeability, VEGF-B plays a role in non-neovascularization tumors, VEGF-C and VEGF-D play a role in the formation of neovascularization and neolymphangiogenesis in cancer tissues, VEGF-E is also a potential neovascularization factor, PGF promotes neovascularization, increases vascular permeability, and PGF expression in experimental choroidal neovascularization is significantly increased.

VEGF begins to be produced in large quantities during the transformation of tumor cell masses into solid tumors, which are most often in the Tis stage and T1 stage of tumors, and is the best stage for tumor screening, and can be diagnosed by the existing clinical means. And other tumor markers are mostly generated in the III stage and the IV stage of tumors, and have little significance for early screening. There is a need to develop diagnostic and prognostic assays that detect measurable levels of VEGF in biological samples of animal models or patients that are higher than existing ELISA, and/or that can measure different isoforms of VEGF.

Disclosure of Invention

In order to solve the technical problems, the invention provides an antibody specifically binding VEGF and application thereof.

The invention is realized by the following technical scheme:

an antibody that specifically binds VEGF, comprising:

CDR-L1 comprising the amino acid sequence of SEQ ID NO:01, and/or

CDR-L2 comprising the amino acid sequence of SEQ ID NO 02, and/or

03, and/or CDR-L3 comprising the amino acid sequence of SEQ ID NO

04, and/or CDR-H1 comprising the amino acid sequence of SEQ ID NO:04

CDR-H2 comprising the amino acid sequence of SEQ ID NO. 05, and/or

CDR-H3 comprising the amino acid sequence of SEQ ID NO: 06.

Further, the antibody is a monoclonal antibody,

alternatively, the antibody is an antibody fragment that specifically binds human VEGF,

optionally, the antibody is a fusion protein comprising an antibody fragment that specifically binds human VEGF,

alternatively, the antibody is a murine antibody,

alternatively, the antibody is a humanized antibody,

optionally, the antibody is a murine monoclonal antibody.

Preferably, the antibody is a humanized monoclonal antibody.

Further, the antibody comprises an antibody heavy chain variable region amino acid sequence comprising a VH sequence set forth as SEQ ID NO 19 or having at least 99% sequence identity to the amino acid sequence of SEQ ID NO 21;

alternatively, the antibody comprises an antibody light chain variable region amino acid sequence comprising a VL sequence as set forth in SEQ ID NO:20 or having at least 99% sequence identity to the amino acid sequence of SEQ ID NO: 22;

preferably, the amino acid sequence of the antibody heavy chain constant region is shown as SEQ ID NO. 21, and the amino acid sequence of the antibody light chain constant region is shown as SEQ ID NO. 22.

Further, the antibody comprises an amino acid sequence of any Fc-terminus selected from the group consisting of human antibodies IgG1, IgG2, IgG3, IgG 4.

Further, the antibody production step comprises: the host cells containing the above-mentioned antibodies are cultured in a medium and under suitable culture conditions, and the produced antibodies and antibody fragments thereof are recovered from the medium or from the cultured host cells.

Further, the invention also comprises the use of the antibody for the preparation of a kit comprising the antibody and other reagents acceptable for its detection use.

In order to achieve the purpose, the invention also provides a detection kit, which comprises any one of the antibodies, particularly a humanized monoclonal antibody, and further comprises an enzyme-labeled coated plate, a standard buffer, an enzyme-labeled solution, a sample diluent, a TMB color developing agent, a washing solution and a stop solution.

Further, the detection kit can be used for auxiliary diagnosis of cancer and intraocular diseases.

Still further, the cancer includes, but is not limited to, leukemia, lymphoma, myeloma, brain tumor, head and neck squamous cell carcinoma, non-small cell lung cancer, nasopharyngeal carcinoma, esophageal cancer, gastric cancer, pancreatic cancer, gallbladder cancer, liver cancer, colorectal cancer, breast cancer, ovarian cancer, cervical cancer, endometrial cancer, uterine sarcoma, prostate cancer, bladder cancer, renal cell carcinoma, melanoma.

The monoclonal antibody of the invention can be well and specifically combined with VEGF, can effectively inhibit the immune function of the VEGF, participates in the tumor immune function, and has the purpose of adjuvant therapy of malignant tumors expressing VEGF tumor cells.

Detailed Description

Definition of

The term "antibody" is used in the broadest sense of the present invention to include a variety of antibody structures, including, but not limited to, monoclonal antibodies, polyclonal antibodies, multispecific antibodies, bispecific antibodies, and antibody fragments, so long as they exhibit the specified antigen binding activity, and the term "antibody fragment" refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds, and antibody fragments including, but not limited to, Fv, Fab', bispecific antibodies, linear antibodies, single chain antibody molecules (e.g., scFv), and/or multispecific antibodies formed from antibody fragments.

The class of antibodies refers to the type of constant domain or constant region that the heavy chain has. There are five main types of antibodies: IgA, IgD, IgE, IgG and IgM, several of which can be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA 2. The heavy chain constant domains corresponding to the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.

The term "IgG" of the present invention is an abbreviation for immunoglobulin G (immunoglobulin G). The term "humanized" of the present invention refers to a chimeric antibody comprising amino acid residues from a non-human HVR and amino acid residues from a human FR. In certain embodiments, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, wherein all or substantially all of the HVRs correspond to those of a non-human antibody, and all or substantially all of the FRs correspond to those of a human antibody. The humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody.

The binding specificity and avidity of an antibody are determined primarily by the CDR sequences, and variants with similar biological activity can be obtained by readily altering the amino acid sequence of the non-CDR regions according to well-established and well-known techniques of the art. It is well known in the art that an antigen binding domain refers to a region that can specifically interact with a target molecule, such as an antigen, with a high degree of selectivity of action, and that sequences recognizing one target molecule are generally unable to recognize other molecular sequences.

The term "binding" of the present invention refers to a non-covalent interaction between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise indicated, the term "binding force" as used herein refers to the intrinsic binding affinity of a 1:1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of a molecule X for its partner Y can be generally expressed by the dissociation constant (KD), and can be measured by common methods known in the art.

The terms "identity", "similarity", and "similarity" of the present invention are the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps to achieve the maximum percent sequence identity, without considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be accomplished in a variety of ways within the skill in the art, including but not limited to using publicly available computer software such as BLAST, ALIGN, or Mega software. One skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms necessary to achieve maximum alignment over the full length of the sequences being compared.

Studies have shown that VEGF is a key factor in the formation of new blood vessels associated with tumors and intraocular disorders. The concentration of VEGF in ocular fluids is highly correlated with the presence of active vascular proliferation in patients with diabetic retinopathy and other ischemia-related retinopathies (Aiello et., N.Engl. J.Med.331:1480-1487 (1994)). Numerous studies have been performed in the past to show a strong correlation between circulating VEGF levels and tumor burden, and suggest VEGF levels as a potential prognostic marker (Gasparini et al, J.Natl. Cancer Inst.89:139 (1997); Kohn Cancer80:2219 (1997)). It is clear that accurate measurement of VEGF has a potentially important role in understanding its role in many biological processes, such as vascular diseases, tumors, intraocular disorders, and the like.

The ability to measure endogenous VEGF levels depends on the availability of sensitive and specific assays. Enzyme-linked immunosorbent assays (ELISA) based on colorimetric, chemiluminescent, and fluorescent assays have been reported for VEGF.

In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention will be described in further detail below.

Example 1:

the method for obtaining the high titer VEGF antibody comprises the following steps:

step 1, mouse immunization: female BALB/c mice of 6 to 8 weeks old were used as experimental animals (purchased from Shanghai Ling-Biotech, Inc.), VEGF-A antigen protein (purchased from Guangzhou Riboao Biotech, Inc.).

And 2, dissolving the antigen protein in normal saline, uniformly mixing 50 mu g of human and isovolumetric complete Freund's adjuvant by adopting a double-pushing method for primary immunization, injecting the mixture into a mouse according to 1 ml/injection amount, and performing subcutaneous multi-point injection on the abdomen.

And 3, performing boosting immunization after 2 weeks, wherein the boosting immunization uses 25 mu g of human VEGF protein and incomplete Freund's adjuvant to be fully mixed to form emulsion, and the emulsion is injected into the abdominal cavity of a mouse according to the injection amount of 0.5 ml/mouse, and the boosting immunization is performed for 3 times.

And 4, after three days of the last immunization, taking venous blood of the mouse, separating serum, measuring the titer of the obtained antibody by an ELISA method, selecting mouse cells with high titer of the antibody, and preparing a single spleen cell suspension by using the mouse.

Step 5, purchasing myeloma cells (SP2/0), culturing the myeloma cells to a logarithmic growth phase, washing the spleen cells obtained in step 4 to prepare an immune single spleen cell suspension, and mixing the myeloma cells and the single spleen cells according to a ratio of 1: 6.

And 6, washing the mixture in a centrifuge tube with incomplete culture solution for 1 time, centrifuging the mixture at the rotation speed of 1200rpm for 8 minutes, discarding the supernatant, uniformly precipitating the cells, preheating the mixture at 38 ℃, adding 1ml of isothermal PEG-4000, quickly adding 25ml of isothermal incomplete culture medium into the mixture to terminate the PEG-4000 reaction after the mixed solution has granular substances, standing the mixture at 30 ℃, adding 2ml of culture medium, and suspending and precipitating the mixture.

Step 7, supplementing the culture medium after mixing until the concentration of splenocytes in the centrifuge tube reaches 2 multiplied by 10⁷and/mL, filling the suspension into a 96-well plate, culturing hybridoma cells, and sucking out supernatant of the suspension for antibody detection when the area of the hybridoma cells is more than half of the area of the bottom of the well.

Example 2:

coating human VEGF (purchased from Riboao Biotechnology Co., Ltd., Guangzhou) on a 96-hole high-adsorption enzyme label plate by using carbonate buffer solution, wherein the coating amount is 100 mu L per hole, and washing the wells for 3 times by using buffer solution; blocking with 1% BSA in buffer and incubating at room temperature for 1 hour, blocking amount 250. mu.L/well, buffer washing 3 times after completion of incubation, adding 100. mu.L of supernatant sample (A1-A85) and positive serum (control, CK1-5) to wells 1-90, respectively, incubating at room temperature for 1 hour, buffer washing 3 times after completion of incubation, adding 100. mu.L of anti-mouse IgG antibody diluted in 1/10000 in 1% BSA-containing buffer per well, the anti-mouse IgG antibody is marked by horseradish peroxidase, incubated for 1 hour at room temperature, washed for 3 times by buffer solution after incubation is finished, 100 mu L of colorimetric substrate 3,3',5,5' -tetramethyl benzidine is added into each hole, color development is carried out for 10min at 30 ℃, then the color development reaction is stopped, OD450nm was read on a microplate reader and positive clones secreting human VEGF-binding antibody were selected according to OD450 nm.

Example 3:

in example 2, three clones GX-81, NX-06, XY-57 having strong antigen binding activity were obtained in total, the clones obtained by screening and having both strong antigen binding activity and antigen neutralizing activity were subjected to nucleotide sequence determination, briefly, the first strand cDNA was synthesized after cell mRNA was extracted, the first strand cDNA generated by reverse transcription was used for the subsequent PCR reaction, the target band obtained by PCR amplification was cloned into pGEM-T vector, and the single clone was picked up for DNA sequencing. Sequencing was performed by Nanjing Kingsri Biotech, Inc.

Obtaining an antibody light chain variable region and an antibody heavy chain variable region through PCR amplification, and obtaining a complementary determining region sequence after eliminating a framework region sequence:

wherein the amino acid sequence of three complementarity determining regions GX-81-CDR-L1 of the GX-81 light chain is shown in SEQ ID NO 1; the amino acid sequence of GX-81-CDR-L2 is shown as SEQ ID NO. 2, and the amino acid sequence of GX-81-CDR-L3 is shown as SEQ ID NO. 3; the amino acid sequences of three complementarity determining regions GX-81-CDR-H1 of the heavy chain are shown in SEQ ID NO. 4, the amino acid sequences of GX-81-CDR-H2 are shown in SEQ ID NO. 5, and the amino acid sequences of GX-81-CDR-H3 are shown in SEQ ID NO. 6.

Wherein the amino acid sequence of the three complementarity determining regions NX-06-CDR-L1 of the NX-06 light chain is shown in SEQ ID NO. 7; the amino acid sequence of NX-06-CDR-L2 is shown as SEQ ID NO 8, and the amino acid sequence of NX-06-CDR-L3 is shown as SEQ ID NO 9; the amino acid sequences of three complementarity determining regions NX-06-CDR-H1 of the heavy chain are shown in SEQ ID NO. 10, the amino acid sequences of NX-06-CDR-H2 are shown in SEQ ID NO. 11, and the amino acid sequences of NX-06-CDR-H3 are shown in SEQ ID NO. 12.

Wherein the amino acid sequence of the three complementarity determining regions XY-57-CDR-L1 of the XY-57 light chain is shown in SEQ ID NO 13; the amino acid sequence of XY-57-CDR-L2 is shown as SEQ ID NO. 14, and the amino acid sequence of XY-57-CDR-L3 is shown as SEQ ID NO. 15; the amino acid sequences of three complementarity determining regions XY-57-CDR-H1 of the heavy chain are shown in SEQ ID NO. 16, the amino acid sequences XY-57-CDR-H2 are shown in SEQ ID NO. 17, and the amino acid sequences XY-57-CDR-H3 are shown in SEQ ID NO. 18.

The antibody light chain constant region amino acid sequence is derived from mouse IgVH and antibody heavy chain constant region sequence mouse IgVH, and the antibody light chain variable region and the light chain constant region are connected to obtain LC full-length sequence; and connecting the heavy chain variable region and the heavy chain constant region of the antibody to obtain a VC full-length sequence.

Example 4:

the variable region sequence and the constant region sequence obtained in example 3 were cloned into a eukaryotic cell expression vector BxB-634 (vector backbone pEGFP-N1), respectively. Antibody light chain and antibody heavy chain expression vectors were transfected into 293F cell lines, the vector backbone pEGFP-N1 was purchased from Haimah organisms, and the 293F cell line was purchased from Shanghai Sphings Biotech, Inc. One day after cell inoculation, transfection was performed, and cells to be transfected were collected by centrifugation and resuspended in fresh expression medium at a cell density of 1X 10⁶cells/mL. Plasmid was added to a final concentration of 54.79. mu.g/mL and linear polyethyleneimine was added to a final concentration of 75. mu.g/mL, according to the transfection volume. And (3) putting the mixture into a cell culture box for culturing for 1 hour (at the culture temperature of 37 ℃), supplementing a fresh culture medium until the final volume is 20 times of the transfection volume, continuously culturing for 5-6 days, collecting a supernatant, and detecting and obtaining the mouse Anti-human VEGF chimeric monoclonal antibodies (GX-81-Anti-VEGF, NX-06-Anti-VEGF and XY-57-Anti-VEGF respectively).

The kinetic constants of the combination of GX-81-Anti-VEGF, NX-06-Anti-VEGF, XY-57-Anti-VEGF murine Anti-human VEGF chimeric monoclonal antibody and VEGF antigen are detected by using an instrument optical surface plasmon resonance technology, and specifically, GX-81-Anti-VEGF, NX-06-Anti-VEGF and XY-57-Anti-VEGF are dissolved in a sodium acetate buffer solution and coupled to a CM chip respectively, and then the CM chip is blocked by 1M ethanolamine.

The binding phase was performed by injecting GX-81-Anti-VEGF, NX-06-Anti-VEGF, XY-57-Anti-VEGF at different concentrations for 5min at a rate of 25. mu.L/min, the dissociation phase was performed for 10min at a rate of 25. mu.L/min with PBS buffer, and the binding kinetic constants and dissociation kinetic constants were analyzed and calculated by Biacore3000 software. The binding kinetic constants, dissociation kinetic constants and dissociation equilibrium constants of GX-81-Anti-VEGF, NX-06-Anti-VEGF, XY-57-Anti-VEGF are shown in Table 1.

TABLE 1 kinetic constants of the binding of murine anti-human VEGF chimeric monoclonal antibodies to their antigens

The results in Table 1 show that GX-81-Anti-VEGF and NX-06-Anti-VEGF can be effectively combined with VEGF antigen, XY-57-Anti-VEGF has weak combination effect with VEGF, GX-81-Anti-VEGF has higher combination rate with antigen, and the following humanized modification is carried out on GX-81-Anti-VEGF and NX-06-Anti-VEGF.

Example 5: preparation of humanized VEGF antibodies

The humanized anti-human VEGF antibody is prepared by referring to the preparation method of the molecular Immunol, a humanized template (Germine database) with the highest matching degree with the non-CDR region of the murine anti-human VEGF chimeric monoclonal antibody is selected, wherein the template of the heavy chain variable region is humanized IgVH4-11 × 03, the template of the light chain variable region is humanized IGKV1-43 × 02, and the CDR region of the humanized template is replaced by the CDR region of the murine antibody to obtain the humanized antibody heavy chain variable region and the humanized antibody light chain variable region.

The amino acid sequence of the H-GX-81-Anti-VEGF heavy chain variable region is shown as SEQ ID NO. 19, and the amino acid sequence of the H-GX-81-Anti-VEGF light chain variable region is shown as SEQ ID NO. 20; the amino acid sequence of the H-NX-06-Anti-VEGF heavy chain variable region is shown in SEQ ID NO:23, the amino acid sequence of the H-NX-06-Anti-VEGF heavy chain variable region is shown in SEQ ID NO:24, the research sequence comparison selects suitable sites for carrying out back mutation, and the amino acid sequence (VH) of the obtained heavy chain variable region and the amino acid sequence (VL) of the obtained light chain variable region are shown in Table 2.

TABLE 2 heavy chain variable region amino acid sequence and light chain variable region amino acid sequence

The heavy chain variable regions (SEQ ID NO:19,21,23,25) of the humanized anti-human VEGF monoclonal antibody were ligated to the human antibody IgG1 heavy chain constant region (SEQ ID NO:28) to obtain the corresponding heavy chain full-length sequences, respectively. The light chain variable regions (SEQ ID NO:20,22,24,26) of the humanized anti-human VEGF monoclonal antibody are connected with the constant region (SEQ ID NO:27) of the light chain of the human antibody IgG1 to respectively obtain corresponding light chain full-length sequences, all the heavy chain full-length sequences and the light chain full-length sequences are combined to obtain the humanized antibody full-length sequence, and the humanized antibody full-length sequence is connected into a BxB-634 vector through enzyme digestion.

And (3) detecting the binding kinetic constant of the humanized VEGF monoclonal antibody and the human VEGF antigen by the same detection method as the example 4, respectively dissolving the humanized VEGF monoclonal antibody to be detected in sodium acetate buffer solution, injecting and coupling the solution onto a CM chip, and then blocking the CM chip by 1M ethanolamine. Humanized VEGF mabs from different test groups were injected at 25. mu.L/min for 3min during the binding phase and 25. mu.L/min for 10min during the dissociation phase, binding and dissociation kinetic constants were calculated analytically by the Biacore3000 software, test groups numbered as follows:

CK1	GX-81-Anti-VEGF
		CK2	NX-06-Anti-VEGF
test set 1	H-GX-81-Anti-VEGF-1
		Test set 2	H-GX-81-Anti-VEGF-2
Test group 3	H-NX-06-Anti-VEGF-1
		Test set 4	H-NX-06-Anti-VEGF-2

The binding kinetic constants, dissociation kinetic constants, and dissociation equilibrium constants of the humanized VEGF mab are shown in table 3.

TABLE 3 kinetic constants for binding of humanized VEGF monoclonal antibodies to their antigens

As shown in the results in Table 3, four groups of humanized VEGF monoclonal antibodies have strong antigen binding capacity, wherein the antigen binding capacity of the tested groups of H-GX-81-Anti-VEGF-2 and H-NX-06-Anti-VEGF-1 is more outstanding.

Example 6:

in order to determine the thermal stability of the H-GX-81-Anti-VEGF-2 and H-NX-06-Anti-VEGF-1 monoclonal antibodies, samples of the H-GX-81-Anti-VEGF-2 and H-NX-06-Anti-VEGF-1 are placed at the high temperature of 40 ℃, samples are respectively taken at the 2 nd week and the 4 th week for SE-HPLC detection to observe the thermal stability, the detection adopts chromatography, and the mobile phases are 0.1mol/L phosphate buffer solution, 0.1mol/L sodium sulfate buffer solution and pH is 6.7; the flow rate is 0.6 mL/min; the temperature of the chromatographic column is 27 ℃; the temperature of the sample cell is 4 ℃; the detection wavelength is 280 nm; the samples were diluted to 2mg/mL loading volume of 20. mu.L with buffer, and the data were processed by calculating the ratio of the main peaks using area normalization, the results are shown in Table 4,

TABLE 4 Single heat stability test results for humanized VEGF

The thermal stability test shows that 2 amino acid sequences all show good and equivalent stability.

Example 7:

the 2 amino acid sequences (H-GX-81-Anti-VEGF-2, H-NX-06-Anti-VEGF-1) can be respectively used for preparing a detection kit, the specific method comprises the steps of preparing an antibody coating microporous plate into a solid phase antibody, sequentially adding a sample into micropores coated with the antibody, adding an enzyme labeling solution marked by HRP to form an antibody-antigen-enzyme labeled antibody compound, thoroughly washing, adding a substrate TMB for developing, converting the TMB into blue under the catalysis of HRP enzyme, converting the TMB into yellow under the action of a stop solution, positively correlating the color depth and the VEGF content, measuring OD under the wavelength of 450nm by using an enzyme labeling instrument, calculating the VEGF content by using a standard curve, and the kit adopts a novel humanized VEGF monoclonal antibody which has stronger binding capacity with human VEGF and higher binding rate and can be used for quickly and accurately detecting the VEGF content, to provide more sensitive and accurate data for aiding in the diagnosis of VEGF related diseases, the kit specifically includes the components set forth in the following Table, detailed in Table 5.

TABLE 5 high sensitivity detection kit for human VEGF

The above disclosure is only for the purpose of illustrating the preferred embodiments of the present invention, and it is therefore to be understood that the invention is not limited by the scope of the appended claims.

Sequence listing

<110> Zhejiang Mass Biotechnology Ltd

<120> antibody specifically binding VEGF and application thereof

<160> 28

<170> SIPOSequenceListing 1.0

<210> 1

<211> 13

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<221> UNSURE

<223> GX-81-CDR-L1

<400> 1

Ile Gln Met Pro Ala Leu Gly Gly Tyr Ile Asn Ala Pro

1 5 10

<210> 2

<211> 8

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<221> UNSURE

<223> GX-81-CDR-L2

<400> 2

Pro Tyr Thr Asp His Trp Ile His

1 5

<210> 3

<211> 9

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<221> UNSURE

<223> GX-81-CDR-L3

<400> 3

Asp Cys Glu His Val Tyr Cys Asn Leu

1 5

<210> 4

<211> 11

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<221> UNSURE

<223> GX-81-CDR-H1

<400> 4

His Pro Pro Gly Gly Cys Gln Asn Asp Ile Leu

1 5 10

<210> 5

<211> 7

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<221> UNSURE

<223> GX-81-CDR-H2

<400> 5

Asp Arg Asp Tyr Ser Cys Trp

1 5

<210> 6

<211> 9

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<221> UNSURE

<223> GX-81-CDR-H3

<400> 6

Tyr Gly Ser Ser His Trp Tyr Phe Asp

1 5

<210> 7

<211> 11

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<221> UNSURE

<223> NX-06-CDR-L1

<400> 7

Ile Gln Met Pro Ala Leu Gly Gly Tyr Ile Asn

1 5 10

<210> 8

<211> 7

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<221> UNSURE

<223> NX-06-CDR-L2

<400> 8

Tyr Thr Asp His Trp Ile His

1 5

<210> 9

<211> 8

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<221> UNSURE

<223> NX-06-CDR-L3

<400> 9

Gly Arg Pro Asn Asp Cys Glu His

1 5

<210> 10

<211> 13

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<221> UNSURE

<223> NX-06-CDR-H1

<400> 10

Pro Met Cys Lys His Ser Pro Asp Cys Tyr Arg Trp Glu

1 5 10

<210> 11

<211> 8

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<221> UNSURE

<223> NX-06-CDR-H2

<400> 11

Gln Ile Asn Glu Glu Phe Phe Leu

1 5

<210> 12

<211> 11

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<221> UNSURE

<223> NX-06-CDR-H3

<400> 12

His Ser Pro Asp Val Phe Gly Asp Cys Tyr Arg

1 5 10

<210> 13

<211> 11

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<221> UNSURE

<223> XY-57-CDR-L1

<400> 13

Glu Leu Trp His Leu Lys Gly Gln Ala Cys Phe

1 5 10

<210> 14

<211> 5

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<221> UNSURE

<223> XY-57-CDR-L2

<400> 14

Gly Arg Arg Lys Pro

1 5

<210> 15

<211> 9

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<221> UNSURE

<223> XY-57-CDR-L3

<400> 15

His Lys Ala Met Trp His Pro His Trp

1 5

<210> 16

<211> 11

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<221> UNSURE

<223> XY-57-CDR-H1

<400> 16

Ile Ala Gly Pro Tyr Glu Asp Asp Asp Ile Arg

1 5 10

<210> 17

<211> 6

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<221> UNSURE

<223> XY-57-CDR-H2

<400> 17

Trp Gly Lys Thr Ser Ser

1 5

<210> 18

<211> 12

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<221> UNSURE

<223> XY-57-CDR-H3

<400> 18

Val Lys Val Leu Thr Asp Gly Ile Pro Pro Thr Glu

1 5 10

<210> 19

<211> 123

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<221> UNSURE

<223> H-GX-81-Anti-VEGF-1 VH

<400> 19

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly His

1 5 10 15

Ser Leu Arg Leu Ser Ile Ser Cys Met Tyr Glu His Pro Pro Gly Gly

20 25 30

Cys Gln Asn Asp Ile Leu Val Pro Lys Gly Ser Phe Pro Thr Thr Asp

35 40 45

Gln Gly Ser Arg Ile Ala Lys Asp Arg Asp Tyr Ser Cys Trp Arg Pro

50 55 60

Glu Phe Phe Gly Leu His Thr Phe Thr Gly Trp Asn Val Glu Gly Asp

65 70 75 80

Trp Trp His Ala Ile Tyr Asn Pro Ala Lys Gln Gln Phe Asn Trp Phe

85 90 95

Ala Lys Tyr Pro His Tyr Tyr Gly Ser Ser His Trp Tyr Phe Asp Val

100 105 110

Phe Gly Gln Gly Thr Leu Val Thr Val Ser Ser

115 120

<210> 20

<211> 109

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<221> UNSURE

<223> H-GX-81-Anti-VEGF-1 VL

<400> 20

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Asp Leu Thr Ala His

1 5 10 15

Met Gly Phe Cys Ser Gln Ile Lys Tyr Ile Gln Met Pro Ala Leu Gly

20 25 30

Gly Tyr Ile Asn Ala Pro Arg Ala Pro Glu Gly Glu Leu Met Ile Ser

35 40 45

Lys Asn Val Ala Trp Cys Phe Pro Tyr Thr Asp His Trp Ile His Phe

50 55 60

Arg Gly Val Ile Asp Leu Thr Tyr Lys Pro Met Leu Met Ala Glu Arg

65 70 75 80

Met Val Thr Gly Arg Pro Asn Asp Cys Glu His Val Tyr Cys Asn Leu

85 90 95

Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys

100 105

<210> 21

<211> 123

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<221> UNSURE

<223> H-GX-81-Anti-VEGF-2 VH

<400> 21

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Ile Ser Cys Met Tyr Glu His Pro Pro Gly Gly

20 25 30

Cys Gln Asn Asp Ile Leu Val Pro Lys Gly Ser Phe Pro Thr Thr Asp

35 40 45

Gln Gly Ser Arg Ile Ala Lys Asp Arg Asp Tyr Ser Cys Trp Arg Pro

50 55 60

Glu Phe Phe Gly Leu His Thr Phe Thr Gly Trp Asn Val Glu Gly Asp

65 70 75 80

Trp Trp His Ala Ile Tyr Met Leu Ala Lys Trp Gln Phe Asn Trp Phe

85 90 95

Ala Lys Tyr Pro His Tyr Tyr Gly Ser Ser His Trp Tyr Phe Asp Val

100 105 110

Trp Gly Gln Gly Thr Leu Val Ile Val Ser Ser

115 120

<210> 22

<211> 109

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<221> UNSURE

<223> H-GX-81-Anti-VEGF-2 VL

<400> 22

Asp Ile Gln Met Thr Asp Gly Pro Ser Ser Leu Asp Leu Thr Ala His

1 5 10 15

Met Gly Phe Cys Ser Gln Ile Lys Tyr Ile Gln Met Pro Ala Leu Gly

20 25 30

Gly Tyr Ile Asn Ala Pro Arg Ala Pro Glu Gly Glu Leu Cys Ile Ser

35 40 45

Lys Asn Val Ala Trp Cys Phe Pro Tyr Thr Asp His Trp Ile His Phe

50 55 60

Arg Gly Val Ile Asp Leu Leu Tyr Lys Pro Met Leu Met Ala Glu Arg

65 70 75 80

Met Asp Thr Gly Arg Pro Asn Asp Cys Glu His Val Tyr Cys Asn Leu

85 90 95

Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Arg

100 105

<210> 23

<211> 124

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<221> UNSURE

<223> H-NX-06-Anti-VEGF-1 VH

<400> 23

Glu Val Gln Leu Val Glu Ser Arg Pro Gly Asn Met Glu Arg Thr Gln

1 5 10 15

Ser Lys Pro Asn Thr Met Glu Ile Asn Val Met Gln Pro Met Cys Lys

20 25 30

His Ser Pro Asp Cys Tyr Arg Trp Glu Met Val Glu Lys Lys Arg Tyr

35 40 45

Asn Trp Pro Asp Asn Ala Glu Gly Arg Leu Leu Tyr His Gln Ile Asn

50 55 60

Glu Glu Phe Phe Leu Asp Trp Leu Pro Trp Tyr Asn Glu Phe Trp Trp

65 70 75 80

Lys Lys Asn Arg His Cys Ser Ser Val Met Phe Ala Lys Tyr Pro His

85 90 95

Tyr Tyr Gly His Ser Pro Asp Val Phe Gly Asp Cys Tyr Arg Gln Gly

100 105 110

Thr Leu Val Thr Val Ser Ser Tyr Val Glu Ile Arg

115 120

<210> 24

<211> 103

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<221> UNSURE

<223> H-NX-06-Anti-VEGF-1 VL

<400> 24

Asp Ile Gln Met Thr Asp Gly Pro Ser Ser Leu Asp Leu Thr Ala His

1 5 10 15

Met Gly Phe Cys Ser Gln Ile Lys Tyr Ile Gln Met Pro Ala Leu Gly

20 25 30

Gly Tyr Ile Asn Ala Pro Arg Ala Pro Glu Gly Glu Leu Cys Ile Ser

35 40 45

Lys Asn Val Ala Trp Cys Phe Tyr Thr Asp His Trp Ile His Arg Gly

50 55 60

Val Ile Asp Leu Leu Tyr Lys Pro Met Leu Met Ala Glu Arg Met Asp

65 70 75 80

Thr Gly Arg Pro Asn Asp Cys Glu His Val Tyr Cys Asn Leu Pro Trp

85 90 95

Thr Phe Gly Gln Gly Thr Lys

100

<210> 25

<211> 124

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<221> UNSURE

<223> H-NX-06-Anti-VEGF-2 VH

<400> 25

Glu Val Gln Leu Val Glu Ser Arg Pro Gly Asn Met Glu Arg Thr Gln

1 5 10 15

Ser Lys Pro Asn Thr Met Glu Ile Asn Val Met Gln Pro Met Cys Lys

20 25 30

His Ser Pro Asp Cys Tyr Arg Trp Glu Met Val Glu Lys Lys Arg Tyr

35 40 45

Asn Trp Pro Asp Asn Ala Glu Gly Arg Leu Leu Tyr His Gln Ile Asn

50 55 60

Glu Glu Phe Phe Leu Asp Trp Leu Pro Trp Tyr Asn Glu Phe Trp Trp

65 70 75 80

Lys Lys Asn Arg His Cys Ser Ser Val Met Phe Ala Lys Tyr Pro His

85 90 95

Tyr Tyr Gly His Ser Pro Asp Val Phe Gly Asp Cys Tyr Arg Gln Gly

100 105 110

Thr Leu Val Thr Val Ser Ser Tyr Val Glu Ile Arg

115 120

<210> 26

<211> 103

<212> PRT

<213> Artificial Sequence (Artificial Sequence)

<220>

<221> UNSURE

<223> H-NX-06-Anti-VEGF-2 VL

<400> 26

Asp Ile Gln Met Thr Asp Gly Pro Ser Ser Leu Asp Leu Thr Ala His

1 5 10 15

Met Gly Phe Cys Ser Gln Ile Lys Tyr Ile Gln Met Pro Ala Leu Gly

20 25 30

Gly Tyr Ile Asn Ala Pro Arg Ala Pro Glu Gly Glu Leu Cys Ile Ser

35 40 45

Lys Asn Val Ala Trp Cys Phe Tyr Thr Asp His Trp Ile His Arg Gly

50 55 60

Val Ile Asp Leu Leu Tyr Lys Pro Met Leu Met Ala Glu Arg Met Asp

65 70 75 80

Thr Gly Arg Pro Asn Asp Cys Glu His Val Tyr Cys Asn Leu Pro Trp

85 90 95

Thr Phe Gly Gln Gly Thr Lys

100

<210> 27

<211> 107

<212> PRT

<213> Homo sapiens

<400> 27

Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu

1 5 10 15

Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe

20 25 30

Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln

35 40 45

Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser

50 55 60

Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu

65 70 75 80

Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser

85 90 95

Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys

100 105

<210> 28

<211> 329

<212> PRT

<213> Homo sapiens

<400> 28

Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser

1 5 10 15

Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe

20 25 30

Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly

35 40 45

Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu

50 55 60

Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr

65 70 75 80

Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys

85 90 95

Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro

100 105 110

Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys

115 120 125

Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val

130 135 140

Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr

145 150 155 160

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu

165 170 175

Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His

180 185 190

Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys

195 200 205

Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln

210 215 220

Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu

225 230 235 240

Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro

245 250 255

Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn

260 265 270

Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu

275 280 285

Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val

290 295 300

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln

305 310 315 320

Lys Ser Leu Ser Leu Ser Pro Gly Lys

325

Claims

1. An antibody that specifically binds VEGF, comprising:

CDR-L1 of amino acid sequence SEQ ID NO:01, and

CDR-L2 of amino acid sequence SEQ ID NO:02, and

CDR-L3 of amino acid sequence SEQ ID NO 03, and

CDR-H1 of amino acid sequence SEQ ID NO:04, and

CDR-H2 of amino acid sequence SEQ ID NO:05, and

the amino acid sequence is shown as CDR-H3 of SEQ ID NO. 06.

2. The antibody of claim 1, wherein said antibody is selected from the group consisting of a monoclonal antibody, an antibody fragment that specifically binds human VEGF, and a fusion protein comprising an antibody fragment that specifically binds human VEGF.

3. The antibody of claim 1, wherein the variable heavy chain amino acid sequence of said antibody is as set forth in SEQ ID NO 21; the amino acid sequence of the antibody light chain variable region is shown in SEQ ID NO. 22.

4. The antibody of any one of claims 1-3, wherein said antibody comprises an amino acid sequence of any Fc terminus selected from the group consisting of human antibodies IgG1, IgG2, IgG3, IgG 4.

5. A detection kit, characterized by comprising the antibody of claim 1, wherein the antibody is a humanized monoclonal antibody, and the kit further comprises an enzyme-labeled coated plate, a standard buffer, an enzyme-labeled solution, a sample diluent, a TMB color developing agent, a washing solution and a stop solution.